// App-Quantinova.ai

: Bridging therapies are not detrimental in patients with hepatocellular cancer waiting for liver transplant: A propensity score analysis

Researchers

Presenter

  • Q. Lai

Principal Investigators

  • U. Cillo

  • S. Iesari

  • A. Finkenstedt

  • M. Rossi

  • E. Tsochatzis

  • G. Otto

  • G.M. Ettorre

  • G. Tisone

  • J. Lerut

Medical Centers

  • La Sapienza, Italy

  • Padua University, Italy

  • UCL, Belgium

  • Sapienza, Rome, Italy

  • The Royal Marsden Hospital, London, United Kingdom

  • Mainz, Germany

  • PTV Rome, Italy

  • PTV Rome, Italy

Locations

  • Italy

  • Belgium

  • Austria

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Alfa-fetoprotein

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved